Happy Nurses Week

In honor of National Nurses week, TapImmune would like to recognize and say thank you for all the hard work and dedication you put in every time you put those scrubs on! Being a nurse can be rewarding and difficult. Without you, patients would be left in the dark. Thank you for being the light for your patients. We especially would like to recognize Oncology Nurses.

Details

World Ovarian Cancer Day

Ovarian cancer is known as the most dangerous and serious gynecologic cancer. What’s even scarier is the women that are important in our lives are at risk of developing this disease. May 8, 2013, was the first World Ovarian Cancer Day. This day was created so that each year, individuals can raise awareness of this horrific disease that takes 140,000 women per year internationally.

Details

AstraZeneca’s IMFINZI™ (Durvalumab) Receives US FDA Accelerated Approval For Previously Treated Patients With Advanced Bladder Cancer

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to IMFINZI™ (durvalumab). IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery.

Details

Exciting Days Ahead

Investor and Industry Conference Apperances These next couple of days are going to be exciting for TapImmune. If you did not have the opportunity to read our press release that was published last Wednesday, our CEO and COO will be speaking at two different conferences. Chairman and CEO, Dr. Glynn Wilson, will be presenting today…

Details